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Abstract  Regenerative  Medicine  is  an  emerging  field  that  combines  basic  research  and  clin-
ical  observations  in  order  to  identify  the  elements  required  to  replace  damaged  tissues  and
organs  in  vivo  and  to  stimulate  the  body’s  intrinsic  regenerative  capacity.  Great  benefits  are
expected  in  this  field  as  researchers  take  advantage  of  the  potential  regenerative  properties
of  both  embryonic  and  adult  stem  cells,  and  more  recently,  of  induced  pluripotent  stem  cells.
Bioengineered  skin  emerged  mainly  in  response  to  a  critical  need  for  early  permanent  coverage
of  extensive  burns.  Later  this  technology  was  also  applied  to  the  treatment  of  chronic  ulcers.
Our  group  has  established  a  humanized  mouse  model  of  skin  grafting  that  involves  the  use  of
bioengineered  human  skin  in  immunodeficient  mice.  This  model  is  suitable  for  the  study  of
physiologic  and  pathologic  cutaneous  processes  and  the  evaluation  of  treatment  strategies  for
skin  diseases,  including  protocols  for  gene  and  cell  therapy  and  tissue  engineering.
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Bioingeniería  cutánea:  aplicaciones  preclínicas  y  clínicas
Resumen  La  Medicina  Regenerativa  es  un  campo  emergente  que  combina  la  investigación
básica y  la  experiencia  clínica  con  el  objetivo  de  proporcionar  los  elementos  necesarios  para
reemplazar  in  vivo  tejidos  y  órganos  dan˜ados,  estimulando  además  la  capacidad  regenerativa
intrínseca  del  organismo.  Se  esperan  grandes  avances  en  este  campo  en  los  próximos  an˜os,de enfermedades
cutáneas;
debido  a  las  potenciales  propiedades  regenerativas  de  las  células  madre  embrionarias  y  adultas,
y  más  recientemente  de  las  células  madre  pluripotentes  inducidas.
 surgió  motivada  principalmente  por  la  necesidad  crítica  de  darLa bioingeniería  cutáneaDermatología
experimental cobertura  permanente  a  grandes  quemados,  y  posteriormente  se  ha  empleado  también  en  el
tratamiento  de  úlceras  crónicas.  Nuestro  equipo  ha  desarrollado  un  modelo  preclínico  human-
izado  basado  en  el  trasplante  de  piel  bioingenierizada  a  ratones  inmunodeficientes  que  posibilita
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1
el  estudio  de  procesos  fisiológicos  y  patológicos  cutáneos,  así  como  la  evaluación  de  estrategias
terapéuticas  de  intervención  dermatológica,  incluyendo  protocolos  de  terapia  génica  y  celular
e  ingeniería  tisular.
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Skin Bioengineering in Clinical Practicentroduction
he  epidermis  regenerates  continuously  through  the  pro-
iferation of  the  epidermal  stem  cells,  a  subpopulation  of
pecialized cells  in  the  basal  layer.1 An  understanding  of
asic epidermal  stem  cell  biology  and  the  mechanisms  gov-
rning the  multipotency  of  these  cells,  together  with  an
nderstanding of  the  genetic  basis  of  various  skin  diseases,
re crucial  components  in  the  development  of  possible
herapeutic strategies  for  clinical  application.  In  fact,  the
uccess of  the  most  novel  skin  tissue  engineering  therapies
ased on  gene  and  cell  therapy  protocols  is  largely  due  to
he fact  that  they  have  managed  to  ensure  that  the  stem  cell
ompartment  retains  its  function.  Over  the  past  15  years,
reat strides  have  been  made  in  the  identification,  isolation,
nd characterization  of  epidermal  stem  cells.2,3
Blood bank
Plasma
Fibrin
Skin donor
Bioengineered dermis
Dermoepidermal equivalent
igure  1  Generation  of  human  dermoepidermal  equivalents.  Fib
re  cultured.  The  fibroblasts  are  then  arranged  on  a  three-dimen
eratinocytes  are  then  seeded  onto  this  artificial  bioengineered  der
T
bThe  possible  therapeutic  use  of  somatic  cells  derived
rom embryonic  stem  cells  is  currently  a  hot  topic  in
egenerative medicine.  Although  skin  biopsies  are  a  regu-
ar source  of  keratinocytes  and  epidermal  stem  cells,  recent
esearch suggests  that  the  generation  of  keratinocytes  from
uman embryonic  stem  cells  could  be  a  useful  technique.4
esearchers  have  also  managed  to  derive  pluripotent  cells
rom adult  keratinocytes.5 Advances  in  this  area  have  been
ruly breathtaking,  and  the  challenge  in  the  coming  years
ill be  to  actually  transfer  all  these  breakthroughs  in  molec-
lar biology  to  routine  clinical  practice.Skin biopsy
Fibroblasts Keratinocytes
roblasts  and  keratinocytes  obtained  from  donor  skin  biopsies
sional  matrix  rich  in  fibrin  obtained  from  blood  plasma.  The
mis  to  form  the  epidermal  component.
o  date,  the  standard  treatment  for  severe  and  extensive
urns is  autografting,  a  technique  based  on  grafting  healthy
2
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aFigure  2  Clinical  application  of  tissue-engineered  skin  equival
fasciitis  (images  courtesy  of  Dr.  Enriquez  de  Salamanca)  and  (B)
skin  from  an  uninjured  area  of  the  patient’s  own  body  to
achieve permanent  regeneration  of  the  skin.6,7 This  strat-
egy is  effective  if  the  damage  is  not  too  extensive  and  there
is enough  undamaged  skin  available.  Autografts  are  usually
taken several  times  from  the  same  area  after  allowing  the
donor site  sufficient  time  to  regenerate.  The  procedure  is
slow, painful,  and  difficult  to  perform  in  patients  with  burns
affecting over  50%  to  60%  of  the  body  surface  area.  The
crucial importance  of  achieving  permanent  skin  cover  in
this setting  has  led  to  the  development  of  bioengineered
skin, which  offers  an  effective  alternative  to  autografts.  This
approach also  avoids  the  pain  involved  in  graft  harvesting,
possible donor-site  complications,  and  the  problem  of  find-
ing a  sufficiently  large  area  of  healthy  skin  on  the  patient’s
own body.  Thus,  different  types  of  bioengineered  skin  have
been developed  over  the  past  20  years.  Although  these  skin
substitutes were  initially  used  as  a  solution  for  acute  skin
loss, they  have  subsequently  been  used  in  various  applica-
tions, including  the  treatment  of  chronic  wounds.8The  ideal
skin substitute  would  be  an  easy-to-handle,  durable,  and
inexpensive equivalent  that  can  mimic  the  physiology  of  nor-
mal skin  and  not  induce  an  immune  rejection  by  the  host.
In general,  the  3  key  elements  in  skin  bioengineering  are  (a)
the cell  source,  (b)  the  regenerative  capacity  of  the  cells,
and (c)  the  matrix  or  scaffold  used.9 Early  skin  substitutes
were composed  solely  of  sheets  of  keratinocytes,  until  it
was established  that  the  inclusion  of  a  biological  template
or scaffold  that  would  act  as  connective  tissue  could  improve
the mechanical  strength  of  the  substitute,  reduce  scarring
and, above  all,  favor  the  persistence  of  functional  epidermal
stem cells  in  vitro  and  in  vivo.10--13
Although  the  perfect  skin  substitute  has  not  yet  been
developed, our  team  has  developed  a  dermoepidermal
equivalent that  has  many  of  the  desired  characteristics
and has  proven  clinically  useful  for  skin  regeneration.13--15
This  bioengineered  skin  consists  of  a  dermis  composed  of
viable human  fibroblasts  seeded  with  keratinocytes,  which
w
g
b
T for  permanent  regeneration  in  the  treatment  of  (A)  necrotizing
the  temporary  coverage  of  chronic  ulcers.
orm  the  epidermal  layer  (Fig.  1).  Of  particular  interest  is
he use  of  a  three-dimensional  fibrin  scaffold  into  which
he fibroblasts  are  embedded.  This  fibrin  matrix,  which
s also  rich  in  growth  factors  and  cytokines,  artificially
eproduces the  normal  healing  process  in  vitro.  After
issue damage,  a  temporary  fibrin  matrix  is  laid  down  that
riggers damage  repair  through  the  migration  of  epithelial
nd mesenchymal  cells  to  the  site.  Thus,  fibrin  is  not
nly a  reservoir  of  different  factors  but  also  provides  an
ppropriate three-dimensional  scaffold  that  promotes  the
igration, proliferation,  and  differentiation  of  cells  in  the
ound bed.13,16 Similarly,  the  human  dermal  fibroblasts
n the  matrix  strongly  induce  keratinocyte  proliferation,
aking it  possible  to  dispense  with  the  use  of  coadjuvant
ouse cells  (a  feeder  layer).14 This  method  reduces  the
nitial skin  surface  required  to  generate  large  areas  of
kin substitute  for  grafting  because  only  very  low  densities
f seeded  keratinocytes  are  required.  Furthermore,  the
ptimum resistance  and  mechanical  stability  conferred  by
he fibrin  matrix  facilitates  both  the  transport  of  these  skin
ubstitutes and  their  handling  during  the  procedure.
All  of  these  properties  are  very  different  from  those  of
ther biomaterials,  such  as  collagen,  which  is  used  in  various
ermal equivalents,  for  example  Apligraf.17 Unlike  fibrin  and
oagulated plasma,  materials  based  on  the  collagen  matrix,
hich has  the  properties  of  quiescent  skin,  do  not  trigger  the
egeneration process.  Consequently,  collagen-based  prod-
cts must  be  seeded  with  keratinocytes  at  densities  close
o confluence.
The skin  equivalent  developed  by  our  team  has  been
sed successfully  in  clinical  applications.  The  autologous
ersion has  been  used  to  achieve  permanent  tissue  regener-
tion in  various  situations  (major  burns,  necrotizing  fasciitis,
ound closure  following  resection  of  giant  nevus,  and  in
raft-versus-host disease).13,15,18 An  allogeneic  version  has
een used  in  the  treatment  of  chronic  ulcers  (Fig.  2).19
he  treatment  of  chronic  ulcers  has  become  important  in
3
Figure  3  Generation  of  a  skin-humanized  mouse  model.  (A--C)  The  skin  obtained  from  the  wound  made  on  the  back  of  the
anesthetized animal  is  devitalized  by  cycles  of  freezing  in  liquid  nitrogen  and  thawing  by  immersion  in  boiling  water.  This  devitalized
skin  is  later  fixed  in  place  over  the  dermoepidermal  equivalent  to  serve  as  a  biological  dressing  that  will  protect  the  skin  equivalent
during  the  grafting  process  and  will  slough  off  naturally  in  approximately  2--3  weeks.  (D--H)  The  dermoepidermal  equivalent  is
orthotopically  transplanted  onto  the  wound  created.  (G--I)  After  14  weeks,  the  images  show  the  appearance  of  mice  bearing
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megenerated  human  skin  (delimited  by  dots),  which  is  clinicall
10).
ecent  decades  owing  to  the  increase  in  life  expectancy
n the  industrialized  world  and  the  associated  increase  in
he prevalence  of  comorbid  conditions,  such  as  diabetes
nd vascular  disease.  The  existence  of  a  potential  market
mounting to  some  2.1%  of  the  total  population  of  developed
ountries has  motivated  the  design  of  various  cell-based
roducts with  potential  clinical  benefits.20
reclinical Applications of Skin
ioengineering:  The Development of a
kin-Humanized  Mouse Model
he  skin-humanized  mouse  model  developed  in  our  labora-
ory is  based  on  transplanting  dermoepidermal  equivalents
enerated using  tissue  engineering  methods  from  donor
broblasts and  keratinocytes  expanded  in  vitro  (Fig.  3).
he regenerated  human  skin  recapitulates  the  main  archi-
ectural and  functional  characteristics  of  natural  human
kin.21 The  persistence  of  the  transplanted  skin  for  a  period
onger than  the  replacement  cycle  of  the  epidermis  under
p
c
a
s histologically  distinct  from  murine  skin  (hematoxylin--eosin,
hysiological  conditions  (approximately  4  weeks)  and  the
orrect differentiation  of  the  epidermal  layers  are  evidence
hat epidermal  stem  cell  function  is  preserved  in  vivo  in
he human  skin  regenerated  on  the  mice.22 The  main  advan-
ages of  this  model  are  the  homogeneity  achieved  and  the
bility to  produce  a  large  number  of  animals  bearing  a  signif-
cant area  of  human  skin  regenerated  at  a  stable  rate  from
 small  biopsy  taken  from  a  single  donor.23The  use  of  bio-
ngineered skin  for  grafts  has  led  to  the  development  of
umanized models  to  facilitate  the  study  of  a  number  of
hysiological skin  processes,  including  wound  healing.  The
n vivo  system  faithfully  reproduces  the  functional  and  struc-
ural  characteristics  of  the  human  healing  process.  This  has
een  demonstrated  through  the  analysis  of  a  wide  variety  of
arameters, such  as  cell  proliferation,  re-epithelialization,
pidermal differentiation,  dermal  remodeling,  and  base-
ent membrane  reorganization.24 The  model  has  also
roved to  be  a  valuable  preclinical  platform  for  evaluating
ell and  gene  therapies  in  the  field  of  dermatology  in  general
nd tissue  regeneration  in  particular.18,25--27 Moreover,  the
ystem can  be  based  on  the  patient’s  own  cells.  Thus,  after
4
Patient with RDEB Skin biopsy Bioengineered
RDEB skin
Skin-humanized mouse
Figure  4  Development  of  humanized  models  of  rare  skin  diseases.  (A)  Human  skin  regenerated  in  immunodeficient  mice  from
cells  obtained  from  patients  with  recessive  dystrophic  epidermolysis  bullosa  (RDEB)  reproduces  the  phenotype  of  this  severe  disease
(B)  as  evidenced  clinically  and  histologically  by  the  presence  of  blisters  (hematoxylin--eosin,  ×20)  (as  indicated  by  asterisks)  and
the  presence  of  type  VII  collagen  in  the  roof  of  the  blisters  (type  VII  collagen,  ×20).
Donor Peripheral
blood
Skin biopsy
Humanized psoriasis model Patient with psoriasis
Bioengineered skin Skin-humanized mouse
Intradermal
injection and
tape-stripping
TH1
Figure  5  Modeling  of  prevalent  skin  diseases.  (A)  Humanized  model  of  psoriasis  based  on  intradermal  injection  in  regenerated
human skin  of  subpopulations  of  T-cells  differentiated  from  a  T  1  phenotype  by  the  injection  of  TH17  type  cytokines  (IL-17  and
IL-22)  followed  by  mechanical  removal  or  disruption  of  the  stratum  corneum  by  tape-stripping.  (B)  The  model  recapitulates  the  key
phenotypic  characteristics  of  the  disease,  such  as  elongation  and  fusion  of  the  rete  ridges,  parakeratosis,  increased  vascularity,  and
dilated  capillaries,  among  others  (hematoxylin--eosin  ×20).  IL  indicates  interleukin.
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1eing  transplanted  to  immunodeficient  mice,  the  regener-
ted human  skin  will  recapitulate  the  patient’s  clinical  and
istologic phenotype.  This  deconstruction--reconstruction
pproach  has  been  used  successfully  to  model  several  rare
onogenic hereditary  diseases  (both  recessive  and  dom-
nant) which  have  devastating  symptoms  and  outcomes
nd for  which  there  is  currently  no  effective  treatment
Fig. 4).  The  genodermatoses  that  have  been  studied  in  this
ay include  skin  fragility  diseases,  such  as  epidermolysis
ullosa,28--30 in  which  blistering  occurs  spontaneously  or  fol-
owing minimal  trauma,  and  skin  diseases  such  as  xeroderma
igmentosum, in  which  mutations  in  DNA  repair  enzymes
ake the  affected  individuals  cancer  prone.31 The  model  has
lso  been  used  in  the  study  of  genetic  diseases  affecting  pro-
iferation and  differentiation  patterns,  such  as  pachyonychia
ongenita32 and  Netherton  syndrome,33 respectively.  Our
eam, working  with  several  European  groups,  has  managed
o correct  cells  from  patients  with  some  of  these  conditions
sing various  gene-therapy  approaches.33--35
Recently,  we  developed  a  model  of  psoriasis,36 a  highly
revalent disease.  In  this  new  humanized  model,  the  incor-
oration of  an  immune  component  into  the  system  has  been
he key  to  recreating  the  classic  plaque  psoriasis  phenotype
Fig. 5).  This  platform  will  allow  us  to  continue  investigat-
ng the  roles  of  the  epidermis  and  the  immune  system  in  this
ery complex  skin  disease.
onclusions and Future
ystems  based  on  bioengineered  skin  like  those  described
n the  present  article  offer  several  advantages,  such  as
he ability  to  grow  keratinocytes  that  retain  their  func-
ionality, including  that  of  the  stem  compartment,  thanks
o the  use  of  a  three-dimensional  fibrin  scaffold  that  pre-
erves the  potency  and  functionality  of  the  epidermal  skin
ells. This  matrix  also  ensures  the  viability  of  the  embed-
ed fibroblasts,  which  are  capable  of  triggering  cell  signaling
o promote  key  tissue  regeneration  processes.  The  bioengi-
eered skin  developed  by  our  group  has  not  only  led  to  the
evelopment of  a  robust  preclinical  platform  for  humanized
odels that  are  being  used  to  evaluate  innovative  strate-
ies, such  as  gene  and  cell  therapies,  it  also  provides  a
linically relevant  alternative  in  the  field  of  skin  regener-
tion that  can  be  used  in  several  diseases.
Our  aim  in  the  near  future  is  to  gain  a  better  understand-
ng of  the  molecular  markers  involved  in  tissue  regeneration
nd repair  and  to  decipher  the  mechanisms  governing  epi-
ermal stem  cell  pluripotency  in  humans.  This  knowledge
ill enable  us  to  model  skin  diseases  that  are  more  complex
han those  described  above  and  to  improve  the  products
erived from  tissue  engineering  in  order  to  develop  skin  sub-
titutes that  can  regenerate  epidermal  appendages,  such  as
air follicles  and  sebaceous  glands.
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